Folate Receptor Alpha (FRα/FOLR1) Immunohistochemical Expression Across Molecularly Classified Endometrial Carcinomas.
The approval of Mirvetuximab soravtansine, a folate receptor alpha (FOLR1)-targeting antibody-drug conjugate, for platinum-resistant ovarian cancer, has prompted interest in FOLR1 as a target in endometrial carcinoma (EC). Characterization of FOLR1 expression across EC histotypes, TCGA molecular subtypes, and clinicall...